# Cabergoline in Nonfunctioning Pituitary Adenomas

Source: https://onco.cc/trials/nct03271918/  
OnCo record `nct03271918` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cabergoline in Pituitary tumours, run by University of Sao Paulo General Hospital, completed.

## Summary

Cabergoline in Nonfunctioning Pituitary Adenomas is a phase 3 interventional study registered as NCT03271918 by University of Sao Paulo General Hospital, with 140 participants recorded, started 2015-02-01 and reaching its primary completion in 2017-02-01. Interventions recorded: Cabergoline. Conditions recorded: Pituitary Adenoma, Nonfunctioning Pituitary Adenoma.

Linked to the drug Cabergoline because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03271918
- Phase: 3
- Setting: Dopamine Agonist Cabergoline in Residual Clinically Nonfunctioning Pituitary Adenoma After Transphenoidal Surgery: A Single Center, Open Label and Randomized Clinical Trial
- Sponsor: University of Sao Paulo General Hospital
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT03271918: https://clinicaltrials.gov/study/NCT03271918

## Connected records

- cancers: [Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma](https://onco.cc/cancers/pituitary-tumours/)
- drugs: [Cabergoline](https://onco.cc/drugs/cabergoline/)

---
JSON: https://onco.cc/api/v1/entities/nct03271918.json